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Introduction
The effect of a bacteriolytic enzyme, the endo-,j-N-acetylglucosaminidase excreted by Staphylococcus aureus (SaG) on the response of human lymphocytes to mitogens and on the immune response in mice has been studied. SaG inhibited incorporation of P3Hjthymidine into TCA-precipitable material by human peripheral lymphocytes stimulated either by phytohemagglutinin or by concanavalin A, as well as formation of cytoplasmic immunoglobulin-containing cells by B lymphocytes treated with pokeweed mitogen. In all cases the level of inhibition first increased with the SaG concentrations reaching values of over 80% at an enzyme concentration of 100 Mg/ml, and then decreased. Heat-inactivated SaG as well as SaG treated with both polyclonal and monoclonal specific antibodies or enzyme inhibitors such as chitotriose or hydrolyzed peptidoglycan had no effect on lymphocyte response to mitogens. In mice, SaG at a dose of 300 ,ug per mouse was found to cause a fourfold decrease in the anti-BSA antibody titer and an -70-75% reduction in the immunoglobulin-containing cells in the spleens of mice injected with sheep red blood cells. SaG also completely abolished the enhancing effect of adjuvants such as muramyldipeptide, Freund's complete adjuvant, and Escherichia coli lipopolysaccharide. When SaG was injected into mice together with S. aureus peptidoglycan hydrolyzed either by SaG or by human lysozyme, the inhibitory effect on both production of anti-BSA circulating antibodies and appearance of Igc cells in the spleens of mice injected with sheep red blood cells was enhanced. As we know that (a) human tissues contain endo-,B-N-acetylglucosaminidases; (b) other human hexosaminidases (lysozymes) have previously been shown to interfere with the functions of immunocompetent cells; and (c) products of hexosaminidase hydrolysis of peptidoglycan (muropeptides) known to modulate immune response are ordinarily found in the urine of healthy persons, the possibility that hexosaminidases play a major role in the regulation of the immune response is raised and discussed. (J. Clin. Invest. 1991 Invest. . 87:1969 Invest. -1976 hydrolyze peptidoglycan and cause bacteriolysis (bacteriolytic enzymes) in the growth medium (1) . More recently, it has been shown that extracellular release of bacteriolytic enzymes is a property common to all strains of some genera ofgreat importance for human pathology, such as the genus Staphylococcus (2) and the genus Enterococcus (3), or a property of all isolates ofthat species which is the most important human pathogen in a given genus, such as Pseudomonas aeruginosa among the Pseudomonadaceae (3) .
Several bacteriolytic enzymes excreted by bacteria have been isolated, purified, and characterized. Among these, those isolated from pathogenic bacteria, namely, Staphylococci and Enterococci, were found to act as hexosaminidases; in particular the enzymes from Staphylococci were found to act as N-acetylglucosaminidases (4) and those from Enterococci as muramidases (5) .
Bacteriolytically active muramidases and glucosaminidases are present in vertebrates, where they are produced by cells of the immune system such as macrophages, monocytes, and granulocytes (6, 7) . Although the role these enzymes play in human physiology is largely unknown, some observations such as the findings that human lysozyme (the muramidase produced by the vertebrate cells mentioned above) regulates the activated state of human polymorphonuclears (8) and that both hen egg white and human lysozyme drastically inhibit the in vitro response of human lymphocytes to mitogens (9) indicate a possible role ofthese enzymes in regulating the activity of nonspecific and specific host defenses. Despite this, the possibility that bacteriolytic enzymes produced by bacteria could interfere with immunocompetent cell functions and with immune response has not yet been considered.
We have previously made the novel and, at the time, unexpected observation that the endo-,B-N-acetylglucosaminidase produced by Staphylococcus aureus (SaG),' an enzyme with substrate specificity very close to that of lysozyme since it hydrolyzes peptidoglycan by splitting the [1] [2] [3] [4] ,B-glucosidic bonds in the same way as lysozyme, but yielding reducing N-acetylglucosamine instead of muramic acid (10) , is capable of interfering with several aspects ofvertebrate cell physiology (1 1, 12) .
Others have shown that endo-O-N-acetylglucosaminidases are produced by cells of some mammals including humans (13, 14) . These facts, together with the well-established knowledge that glucosaminidases of the exo type share the property of being produced by cells of the immune system with lysozyme (15) , prompted us to evaluate the possibility that SaG might interfere with human lymphocyte functions and, perhaps, with the immune response in mammals.
In this work we show that SaG prevents in vitro response of human lymphocytes to mitogens and strongly interferes with the immune response of mice, significantly reducing production of circulating antibodies and completely abolishing the enhancing effect of muramyldipeptide, Freund's complete adjuvant, and Escherichia coli lipopolysaccharide.
Methods
Purification ofS. aureus glucosaminidase, bacteriolytic activity assay, and purity criteria. SaG was purified and its lytic activity measured turbidimetrically as described previously (4) . Human lysozyme (HL) was purified from urine of a patient with monocytic leukemia as described previously (12) .
The purity of each different SaG preparation was checked by SDS-PAGE (16) by loading up to 1 mg of proteins on wells in 3-mm thick gel. In addition to this, protease, lipase, phosphatase, heat-stable DNase, coagulase, and hemolytic and leucocidin activity were each tested using samples containing at least 1 mg of proteins. Coagulase activity was assayed as described elsewhere (17) by adding 0.2 ml of pure SaG preparation to 2 ml of rabbit plasma. Protease, lipase, phosphatase, and heat-stable DNase were assayed as described (18) (19) (20) (21) , respectively, by depositing 0.1 ml ofpure SaG preparations (sterilized by filtration) in adequate wells prepared in the specific solid media. Positive controls were represented by protease type I from bovine pancreas, lipase type VI-S from porcine pancreas, phosphatase type I from bovine intestine, and deoxyribonuclease I type II from bovine pancreas (Sigma Chemical Co., St. Louis, MO). Plates were incubated for 12 h at 370C and then observed. Hemolysis was assayed on blood agar plates prepared according to current criteria (17) with rabbit or sheep erythrocytes by depositing 0.1 ml of the pure and filtration sterilized SaG preparation onto the plates, which were incubated for 12 h at 37°C. Leucocidin activity was assayed following the procedure described by Noda et al. (22) . Only preparations that gave only one band in the SDS-PAGE ( Fig. 1 ) and did not contain any ofthe biological activities mentioned above in 1 mg protein, were used in all the experiments. All experiments described throughout this work were carried out using at least two different enzyme preparations from the same staphylococcal strain (AT12). Some of the most crucial experiments were further repeated using SaG Other test substances and chemicals. Tri-N-acetylglucosamine (chitotriose) and anti-SaG antisera were prepared in our laboratory. Chitotriose was obtained by partial acid hydrolysis of chitin (ICN Pharmaceuticals, Plainview, NY) followed by charcoal column fractionation, as described by Rupley (25) . Specific anti-SaG antisera were obtained from rabbits, using SaG preparations that met the above-described criteria for purity. The initial antigen dose was given intramuscularly as a water-in-oil emulsion with CFA (Difco Laboratories Inc., Detroit, MI). Two booster doses were given subcutaneously as emulsions with incomplete Freund's adjuvant (Difco) 10 To determine the effect of SaG on the enhancing effect of immunoadjuvants, muramylpeptide (MDP; Protein Research Foundation, Tokyo) and lipopolysaccharide ofE. coli 055:B5 (Difco) were also employed. Lysostaphin, bovine pancreatic RNase, and poly-L-lysine (mol wt 4,000-15,000) were purchased from Sigma Chemical Co.
Other methods. To estimate the effect ofSaG on lymphocyte viability, 0.9 ml ofcell suspensions was mixed with 0.1 ml of 1% trypan blue saline solution. The suspensions were examined microscopically after 30 min exposure ofthe cells to the dye, and the numbers ofstained and unstained cells were analyzed. The results were compared to controls without SaG and expressed as percentage of viable cells.
S. aureus peptidoglycan was purified using the same procedure used for purifying the M. luteus peptidoglycan (4) . Purity of the polymer was checked by determining the amino acid composition after hydrolysis in 6N HCI for 18 h at 100IC with an automatic amino acid analyzer (I 19; Beckman Instruments, Inc., Fullerton, CA). The peptidoglycan preparation was considered pure when at least 95% ofamino acids present were those of the S. aureus peptidoglycan in their typical molar ratio. For enzymatic digestion of peptidoglycan, SaG or HL was added to a suspension of 1 g pure peptidoglycan ofS. aureus in 99 ml of 0.15 M sodium acetate buffer at a final concentration of 100 Ag/ml and incubated at 370C for 6 h. The insoluble material was removed by centrifugation (150,000 g for 3 h) and the supernatant was lyophilized.
To obtain trypsin-inactivated SaG, a solution of 200 .g/ml of SaG was added with 20 ,g/ml oftrypsin and incubated at room temperature up to complete inactivation of SaG bacteriolytic activity. Ovomucoid was then added to the mixture to inactivate trypsin. Boiled SaG and heat-inactivated SaG were prepared by 15 min heating at 100IC and 20 min heating at 120'C, respectively. Determination ofpossible residual lytic activity after heating and enzymatic digestion, and in the presence of both monoclonal and polyclonal antibodies and chitotriose, was performed according to the standard procedures referred to above for assay of lytic activity (4) .
MAbs to pure SaG (and to lysostaphin) were prepared following standard protocols (26) . A total offive different MAbs capable ofbinding SaG was obtained. The one that gave the highest inhibition of SaG bacteriolytic activity was used in this work. A monoclonal antibody capable of inhibiting lysostaphin bactenolytic activity was also obtained.
Results
SaG prevents human lymphocyte response to Con A and PHA.
SaG inhibited incorporation ofradioactive thymidine by mitogen-treated lymphocytes both when the enzyme was present in the cultures and when it was used to pretreat the cells before mitogenic stimulation (Fig. 2) . The level of inhibition depended on the enzyme concentration, first increasing and then decreasing as the enzyme concentration increased. When added together with the mitogen, SaG caused inhibitions ofup to -75 and 85% for Con A and PHA, respectively (Fig. 2 A) . When the enzyme was removed immediately before mitogen treatment, inhibition was also substantial, being 65% for Con A and > 85% for PHA (Fig. 2 B) . Under the latter conditions the inhibitory effect caused by SaG was reversible. It was maintained for 20-30 min after removal of the enzyme (in both PHA and Con A) and then began to drop, being completely absent after 50-60 min (Fig. 3) . In the latter, the absolute values yielded by the five experiments ranged from 39,000 to 57,000 cpm for Con A, and from 56,000 to 77,000 cpm for PHA. The cpm values were consistently below 5,000 in the unstimulated control cultures (i.e., not exposed to Con A or PHA). [29] ), did not demonstrate any effect on lymphocyte response to mitogens. It is also important that the monoclonal antibody that prevented the inhibitory effect of SaG on the human lymphocyte response to mitogenic stimulation also abolished the bacteriolytic activity ofthe enzyme. In contrast, both monoclonal and polyclonal antibodies specific for another staphylococcal protein (lysostaphin) had no effect on the inhibitory activity of SaG. SaG interferes with anti-BSA antibody production in mice.
To test whether SaG in vitro inhibition oflymphocyte response to mitogenic stimuli might be a manifestation of a possible modulating activity ofthe enzyme on immunocompetent cells, we analyzed the effect of SaG on antibody production in mice. Table II shows that SaG demonstrated a clear inhibitory effect, as evaluated by determination both of anti-SRBC antibodycontaining cells in spleens ofimmunized mice and ofanti-BSA circulating antibodies (again in mice). In both systems the inhibitory effect increased with enzyme concentration, reaching a maximum at the concentration of 300 ag/mouse. This SaG dose caused a 3.6 and a 4-fold reduction in antibody production in the former and in the latter system, respectively. Boiled SaG maintained its inhibitory activity which, in contrast, was completely lost after autoclaving. Moreover, trypsin-digested SaG, injected together with the antigens, had no effect on the mouse immune response in either of the two experimental systems. Two other cationic peptides devoid of glucosaminidase activity, lysostaphin (see above) and polylysine, did not influence production ofanti-BSA circulating antibodies, but caused a slight increase in the number of anti-SRBC immunoglobulin-containing cells detectable in the spleens of immunized mice.
When the experiments described in Table II were repeated using SaG purified from another S. aureus strain (A 128), antibody production was again inhibited in both experimental systems at levels virtually identical to those observed with SaG purified from strain AT 12.
SaG completely abolishes the enhancing effect ofimmunoadjuvants. In mice where BSA was injected together with any one of the immunoadjuvants MDP, LPS, or CFA, the anti-BSA antibody titer was four to eight times higher than that found in mice injected with BSA only (Table III) . However, when 300 ,g of SaG was injected together with the antigen and one of the three adjuvants, the anti-BSA antibody titer was in all cases lower than that of the controls injected with the antigen only. It is interesting that identical results were obtained when SaG purified from a different S. aureus strain was used. In contrast to this, neither SaG inactivated by autoclaving, nor polylysine or lysostaphin, interfered with the enhancing effect of any of the three adjuvants. S. aureus peptidoglycan solubilized either with human lysozyme or with SaG enhances the inhibitory effect of SaG on antibody production in mice. Insoluble peptidoglycans have been shown to enhance antibody production (30) . In addition, both insoluble and hydrolyzed peptidoglycans are competitive inhibitors of bacteriolytic enzymes (see also Table I ). In infections caused by S. aureus SaG must always be present together with staphylococcal wall peptidoglycan that is likely to be partly in a soluble form due to the hydrolytic activity of the lysozyme of human tissues and of bacterial autolysin(s). This fact raises the possibility that the inhibitory effect of SaG in infections could be prevented by peptidoglycan (in the soluble or insoluble form). Table IV shows that S. aureus peptidoglycan, whether insoluble or hydrolyzed by HL or SaG, when injected into mice together with antigens, slightly enhances both production of anti-SRBC immunoglobulin-containing cells in the mouse spleens and production ofanti-BSA circulating antibodies. On the contrary, when SaG was injected together with the antigens and the hydrolyzed peptidoglycan, not only was the enhancing effect of the peptidoglycan completely abolished, but the inhibitory effect of SaG on immune response was slightly, though unquestionably, enhanced. In fact, under these conditions the number ofanti-SRBC immunoglobulin-containing cells in the spleens and the titer ofthe anti-BSA circulating antibodies were more than 8 and 12 times lower, respectively, than in controls injected with the antigens only. Insoluble peptidoglycan did not appear to influence the inhibitory effect of SaG, but its enhancing effect was abolished. In addition, neither autoclaving-inactivated SaG, nor polylysine or lysostaphin interfered with the enhancing effect on the immune response caused by both insoluble and solubilized peptidoglycan in the two different systems.
Discussion
This work presents a number of novel observations that were rather unexpected, based on our current knowledge ofthe possible biological effects of peptidoglycan hydrolytic enzymes produced by bacteria. We have, in fact, shown here that an endo-,f-N-acetylglucosaminidase excreted by one of the most important human pathogens almost completely inhibits formation of blasts and immunoglobulin-containing cells after treatment with mitogens, strongly depresses the immune response in mice, and completely abolishes the enhancing effect of the most powerful adjuvants. The possibility that peptidoglycan hydrolytic enzymes may interfere with host defenses has never been considered before. This is the first description ofa hexosaminidase (namely an endo-fl-N-acetylglucosaminidase) interfering with antibody production in mice and the first description of a microbial bacteriolytic enzyme preventing in vitro response of human lymphocytes to mitogens and impairing immune response in mice. Such findings are important for a better understanding of the mechanisms by which bacteria express their pathogenicity and for further clarifying the mechanism of regulation of the immune response.
As far as the former problem is concerned, we have already stated that bacteriolytic enzymes, many ofwhich act as endowfi-N-acetylglucosaminidases (4, 5) , are secreted by various microbial species that are important in human pathology (2, 3) . In most ofthese cases, the virulence determinants ofthe microorganism are as yet unknown. Our findings suggest the possibility that, in S. aureus and in other species that produce enzymes of the SaG type, the bacteriolytic enzyme is one ofthe pathogenicity determinants. This is strongly supported by the fact, as (33) . We should also consider that proteins are rapidly metabolized by living animals and that the metabolism of mice is much faster than that of humans. In infections SaG is continuously produced by the infecting staphylococci thus replacing the enzyme metabolized (and destroyed) at the host organism. On the other hand the amount of SaG which, after administration of 300 tg to mice, arrives at immunopoietic organs such as lymph nodes distant from the site ofinjection, is so low that it is likely that an equivalent amount can easily be produced by staphylococci that invade regional lymph nodes in natural infections in humans. It is therefore likely that, as a result of the SaG released, staphylococci that multiply in the lymph nodes may cause impairment of the immune response in the invaded organ, even when they are not present as large populations.
Lastly it is interesting to recall that, during phagocytosis of staphylococci and other bacteria, human granulocytes release lysozyme and other hexosaminidases (exo-fl-N-acetylglucosaminidase) at high concentrations. Since we have found that hen egg white lysozyme also inhibits antibody production in mice, it is possible that such enzymes may exert an effect ofthe type observed with SaG thus determining further impairment of host defenses. We have previously shown that, in some Gram-positive and Gram-negative pathogens, the different species can be identified, for both taxonomic and clinical purposes, on the basis ofthe peculiar properties ofthe bacteriolytic enzymes the strains secrete (2, 3, 34) . The finding that such enzymes may contribute to microbial pathogenicity relates this identification system to a pathogenicity determinant and makes it particularly suitable for separating the different staphylococcal species that may be clinically important.
The relevance of the findings described here for a better understanding of the mechanism of immunocompetent cell regulation appears evident when such findings are taken together with other observations. We have recently shown that both HL and hen egg white lysozyme (i.e., endo-hexosaminidases that hydrolyze peptidoglycan with a mechanism very similar to that of SaG) inhibit the response ofhuman lymphocytes to mitogens (9) . Others have demonstrated that HL regulates the activated state of human granulocytes (8) and contributes to regulation oflymphocyte proliferation in mixed lymphocyte cultures (35) . In addition to this, exo-f3-N-acetylglucosaminidases have long been known to be produced by macrophages, monocytes, and granulocytes (15, 36) while an endo-f3-N-acetylglucosaminidase has been purified from hen oviduct (37) and has been described in tissues of humans and other mammals (13) . More recently, an exo-fl-N-acetylglucosaminidase that hydrolyzes peptidoglycan has been shown to be carried by human granulocytes (38). On the other hand, it is well established that both polymeric peptidoglycan and peptidoglycan glycopeptides (which are substrates and competitive inhibitors of these enzymes) have an immunomodulating effect (30, 39) . It is also known that bacterial peptidoglycan undergoes extensive turnover (up to 50% per generation) during which a variety of glycopeptides (muropeptides) are released (40) . Probably as a consequence of this, muropeptides are ordinarily found in urine of people who do not suffer from infections (41) . All the above-mentioned observations together with the findings of this study make it very likely that hexosaminidases that hydrolyze peptidoglycan play a role in the regulation of immune response and that the alterations which peptidoglycan and peptidoglycan derivatives, such as MDP, cause in immune response may be due to their interaction with these enzymes. Knowledge of these previously unknown facts may be the starting point for a novel approach to the study of regulation of immune response.
All the information mentioned above also provides a probable explanation ofthe mechanism by which SaG interferes with the response of human lymphocytes to mitogenic stimuli and with antibody production in mice. Hexosaminidases may perform their possible regulatory function by operating on a double pathway, where, on the one hand, they interact directly with immunocompetent cells by binding with specific receptors and, on the other, they generate (from bacterial envelopes) muropeptides that modulate hexosaminidase interaction with the aforementioned receptors, and also directly interact with effector cells. In this context, SaG may cause inhibition of the in vitro response of human lymphocytes to mitogens by binding to specific receptors through which it triggers, in the specific cells, nonresponse to mitogenic stimuli. Some of the data in our possession actually indicate that SaG binds specific receptors of immunocompetent cells. However, the mechanism by which SaG exerts its effect is probably rather complex, as indicated by the fact that hydrolyzed peptidoglycan of S. aureus, which is a competitive inhibitor ofSaG (and other bacteriolytic hexosaminidases), induces slight though distinct enhancement ofdepression ofantibody production caused by SaG in mice. It is possible that immunocompetent cells carry two components that act as receptors for SaG (and probably for other hexosaminidases including the endogenous ones), of which one has high and one low affinity for the enzyme. The first receptor, which is bound at low concentrations of SaG, triggers the nonresponse effect, while the latter, bound at higher concentrations only, antagonizes the effects ofthe former. At the concentrations needed for saturating the high affinity receptor, SaG may partially bind the low affinity receptor which to a certain extent moderates depression of response. The solubilized peptidoglycan might have an affinity for SaG that is lower than that of the high-affinity receptor, but higher than that of the low-affinity receptor, and may thus prevent binding of SaG (and other hexosaminidases) to the receptor potentially responsible for antagonizing response depression. Alternatively, muropeptides present in the body might normally stimulate im-munocompetent cells. SaG and other hexosaminidases may contribute to regulation of immune response both by generating such muropeptides and by modulating their interaction with the target cells.
